0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Cerebral-related Solutions & Services

Cerebral-related
Solutions & Services

Explore our ready-to-use cerebral organoids, cells, and services. Learn about how we can assist with disease modeling, organoid differentiation, and drug testing, encompassing cell activity assays and electrophysiological measurement platforms to provide reliable insights into neuroscience research.

Inquire About Our Solutions

Cerebral Organoids

Cerebral organoids are a miniaturized, in vitro version of the brain that is derived from induced pluripotent stem cells (iPSCs). These organoids are designed to have a similar cellular composition and architecture as the brain, exhibiting similar mechano-physiological and electrophysiological properties. As such, cerebral organoids are critical tools for researchers developing treatments to neurological diseases, driving different applications such as:

Neurological Drug Screening

Neurological
Drug Screening

Neurological
Drug Screening

Organoid-based cerebral models provide a scalable, high-throughput drug screening assay for drug efficacy and toxicity.

Neurological Disease Modeling

Neurological
Disease Modeling

Neurological
Disease Modeling

Cerebral models are an alternative to animal models, providing a more physiologically relevant platform that models diseases such as Parkinson’s and Alzheimer’s.

AAV Serotype Screening

AAV
Serotype Screening

AAV
Serotype Screening

Adeno-associated viruses are a critical gene delivery tool. Finding the right serotype for gene transduction into the target tissue type can make or break gene therapies.

Neurodevelopmental Research

Neurodevelopmental
Research

Neurodevelopmental
Research

Neurodevelopmental research strives to learn about the formation of the nervous system during development, such as generation, migration, connectivity and more.

Cerebral organoids and differentiation kits are available to support high-throughput differentiation of brain organoids from iPSCs.

3-step organoid differentiation kit to efficiently generate up to 96 units.
Cellular composition including neuron and glial cells with brain-like structures.
Spontaneous electrophysiological activity in response to toxic reactions induced by pre-formed fibril addition.

Cerebral organoids and differentiation kits

Immunostaining of 119-day old cerebral organoid for OLIG2 and TUJ1 reveals the distribution of oligodendroglia and mature neuron cells, respectively.

Product List

Cat. No.Description
CIPO-BWL001KReady-to-use Human iPSC-Derived Cerebral Organoids
RIPO-BWM001KHuman iPSC-Derived Cerebral Organoid Differentiation Kit
RIPO-BWM003Human iPSC-Derived Cerebral Organoid Maturation and Maintenance Kit
RIPO-BWM006Cerebral Organoid Cryopreservation Kit

Cerebral Cells

Cerebral Cells

Neural progenitor cells are the progenitor cells that develop into glial and neuronal cells that populate the central nervous system. They possess the ability to self-renew and secrete neurotrophic factors that are crucial in promoting neural regeneration.

Cerebral Cells

Neural progenitor cells are the progenitor cells that develop into glial and neuronal cells that populate the central nervous system. They possess the ability to self-renew and secrete neurotrophic factors that are crucial in promoting neural regeneration.

Product List

Cat. No.Description
CIPC-NDC001Human iPSC-Derived Neural Progenitor Cells (Parkinson's disease)
CIPC-DDC001Human iPSC-Derived Dopaminergic Neurons (Parkinson's disease)
CIPC-NWC001Human iPSC-Derived Neural Progenitor Cells
CIPC-DWC001Human iPSC-Derived Dopaminergic Neurons

Cerebral Services

Organoid Differentiation and Validation Services

We offer differentiation services to develop cerebral organoids from iPSCs or human tissue. Organoids are validated by the expression of brain-related protein markers to ensure differentiation and maturity.

Experiments Performed:
Cerebral differentiation
Validation by WB, IF, qPCR for MAP2,TH and Morphological evidence
Deliverables:
Customed Cerebral organoids
Raw data and images
Detailed validation test report

Organoid Differentiation and Validation Services

Cerebral Toxicity Studies

We can measure the inhibitory effect of electrical signals blocking drugs and the cell viability of neuron cells to better predict drug cerebral toxicity.

Experiments performed:
Cell Toxicity screening test (2D/3D)
Electrophysiological test (2D/3D),Calcium imaging and patch clamp analysis
We can provide:
Detailed toxicity test report
Raw data and images

Cerebral Toxicity Studies

AD / PD Disease Modeling

We can help to construct the AD/PD model with PFFs and provide corresponding pathological findings and biochemical evidence. At the same time, we can also provide you with follow-up drug screening services.

Experiments Performed:
AD/PD model construction on organoids
Validation Methods include WB, IF, qPCR for Aβ,pTau,α-Syn, etc. MEA is performed for viability and pathological characterization for validation.
Deliverables:
Raw data and pictures
Detailed validation test report
Customed AD/PD model based on organoid

AD / PD Disease Modeling

Vascularized Cerebral Organoids and Blood–brain barrier (BBB)-on-a-chip are coming soon!

Interested? Leave a message!

Cerebral Case Studies

Alzheimer’s Disease Modeling – Detection of Cerebral Cells

Developed using our organoid differentiation kit, 55-day old cerebral organoids derived from iPSCs were incubated with varying concentrations of Tau pre-formed fibrils. Anti-pTau antibodies were used to visualize Tau aggregation alongside MAP2 staining to visualize mature neurons.

Alzheimer’s Disease Modeling
Results:

Aggregation of Tau was visualized in organoids incubated with Tau pre-formed fibrils, represented by the thickening of lines in red. Increasing concentration of PFFs resulted in a more noticeable aggregation of Tau.

Parkinson’s Disease Modeling – Detection of Cerebral Cells

Developed using our organoid differentiation kit, cerebral organoids derived from iPSCs were incubated with varying concentrations of α-synuclein pre-formed fibrils. TH staining was used to visualize dopaminergic neurons, with MAP2 representing mature neurons.

Parkinson’s Disease Modeling
Results:

With the addition of α-syn PFFs into the organoid model, swelling of axon microtubules and neuron density loss is visualized. In comparison to control, significant microtubule loss (thin green lines) suggests oxidative stress stemming from addition of PFFs.

AAV Screening with Cerebral Organoids

Several AAV serotypes were utilized to evaluate transgene efficacy using cerebral organoid models. Evaluation of the resulting expression of delivered GFP transgene was compared to evaluate transduction and select the optimal AAV serotype in comparison to commercial wild-type AAVs. Cerebral organoids grown for 101 days were infected with 1E+11 μg of AAV5-WT (left), IVB-1 (middle), and IVB-2 (right).

AAV Screening with Cerebral Organoids
Results:

The IVB-2 subtype showed a significantly higher level of infectiousness revealed by the high levels of GFP expression in cerebral organoids.

Assessment of Neurotoxicity with Cerebral Organoids (Muscimol)

Compared neuronal activity in organoid cultures between a control group and a group treated with Muscimol, a GABAA receptor agonist.

Assessment of Neurotoxicity with Cerebral Organoids (Muscimol)
Results:

The control organoid (top) showed robust network burst activity and a high mean spike firing rate. In contrast, the Muscimol-treated organoid (bottom) exhibited decreased burst activity and a lower mean spike firing rate, indicating inhibitory modulation of neuronal excitability.

Assessment of Neurotoxicity with Cerebral Organoids (Picrotoxin)

A subset of organoids was treated with Picrotoxin, a compound known to block GABAA receptor-mediated inhibition. Extracellular recordings were performed using multi-electrode arrays (MEAs) to monitor neuronal activity.

Assessment of Neurotoxicity with Cerebral Organoids (Picrotoxin)
Results:

Picrotoxin-treated cerebral organoids showed synchronized bursting activity, an indicator of synaptic maturation.

Related Products

>> Aneuro, Advance Neuroscience Research

References

1. Hernandez-Baltazar, Daniel, et al. "Animal model of Parkinson disease: Neuroinflammation and apoptosis in the 6-hydroxydopamine-induced model." Experimental Animal Models of Human Diseases [Internet]. Rijeka: InTech (2018): 375-393.

2. Chongyuan Luo, et al. Cerebral Organoids Recapitulate Epigenomic Signatures of the Human Fetal Brain. VOLUME 17, ISSUE 12, P3369-3384, DECEMBER 20, 2016.

ACRO Quality

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje